By acting on both systems at once, tirzepatide can deliver stronger effects on appetite, fullness, and metabolic health than GLP-1 medications alone
Patients and clinicians should be aware that reflux-type symptoms are biologically plausible and have been reported in trial settings for this drug class, even if a definitive causal link has not been formally established for retatrutide specifically
Unveiling promising neuroimaging biomarkers for schizophrenia through clinical and genetic perspectives
Laboratory equipment is calibrated and maintained
Prescription nootropics include stimulants and non-stimulant medications
M., Ferrucci, L., Maraldi, C., Balfour, J., & Kritchevsky, S